Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy-Reference-Cited by-同舟云学术

Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy

Published:2018-07-30 Issue:12 Volume:25 Page:1446-1451
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Hayashi Kazuhiko¹²^ORCID,Ishigami Masatoshi²^ORCID,Ishizu Yoji²,Kuzuya Teiji²,Honda Takashi²,Hirooka Yoshiki²,Toyoda Hidenori³,Kumada Takashi³,Hattori Masashi⁴,Katano Yoshiaki⁵,Goto Hidemi¹²

Affiliation:

1. Department of Gastroenterology and Hepatology; Meijo Hospital; Nagoya Japan

2. Department of Gastroenterology and Hepatology; Nagoya University Graduate School of Medicine; Nagoya Japan

3. Department of Gastroenterology; Ogaki Municipal Hospital; Ogaki Japan

4. Department of Gastroenterology; Yamashita Hospital; Ichinomiya Japan

5. Department of Internal Medicine; Banbuntane Hotokukai Hospital; School of Medicine; Fujita Health University; Nagoya Japan

Funder

Japan Agency for Medical Research and Development

AbbVie

AstraZeneca

Bristol-Myers Squibb Foundation

Chugai Pharmaceutical

Daiichi-Sankyo

Dainippon Sumitomo Pharma

Esai

Mitsubishi Tanabe Pharma

Merck

Otsuka Pharmaceutical

Takeda

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12967/fullpdf

Reference17 articles.

1. Natural history of chronic hepatitis C;Seeff;Hepatology,2002

2. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders;Chayama;Hepatology,2012

3. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir;Karino;J Hepatol,2013

4. A comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b;Hayashi;J Gastroenterol Hepatol,2018

5. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin;Swain;Gastroenterology,2010

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals;Journal of Medical Virology;2024-05

2. Long-term durability of sustained virologic response for hepatitis C virus infection in solid organ transplant recipients receiving direct-acting antivirals;Journal of the Formosan Medical Association;2023-08

3. Management of dialysis patients with hepatitis C virus in the era of direct‐acting antiviral therapy;Therapeutic Apheresis and Dialysis;2023-05-22

4. Repeated Hepatitis C Virus Recurrence in a Patient With a Prognosis of Ultimate Spontaneous Clearance: Relapse or Reinfection?;American Journal of Therapeutics;2023-01-18

5. Ledipasvir/Sofosbuvir is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir;Internal Medicine;2023